Helixate FS, Mix2Vial now packaged together


CSL Behring has begun packaging Helixate FS, its advanced recombinant FVIII (rFVIII) factor product for the treatment of hemophilia A, with Mix2Vial, its needle-free transfer device. The new packaging was developed in response to comprehensive market research of customers and to meet the latest OSHA requirements. For more information, visit

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.